Articles related to DRUG COSTS

The Inflation Reduction Act’s out-of-pocket cap on Medicare Part D spending marks a pivotal shift in healthcare economics, potentially altering prescription drug cost dynamics for millions of enrollees. Physicians should be aware of these changes to better support and inform their patients navigating these new financial landscapes.

In an era where specialty drug costs soar, Alternative Funding Programs present a complex solution, balancing cost containment with patient access to essential medications. These programs, while offering potential savings, may also introduce treatment delays and increased financial burdens for patients.

The study’s findings underscore the importance of addressing the high cost of insulin. Despite new products and discounts entering the market, one in four patients still report cost as a barrier to accessing their necessary insulin.

Discover how the Inflation Reduction Act influences pharmaceutical innovation and drug pricing. Learn why delaying drug launches might not be an optimal strategy.

Discover how a recent class-action lawsuit against Bristol Myers Squibb could impact the availability and cost of multiple myeloma treatment options.

Discover how the 340B Drug Pricing Program influences prescription trends toward higher-cost biologics over biosimilars, and what this means for cost-effective healthcare.